Pankaj C. Gupta
Advanced in Corneal Dystrophy and Perceptive Deafness

Dr. Pankaj C. Gupta

Ophthalmology
Spectrum Eye Care, Inc.
15840 Medical Dr S, Suite A, 
Findlay, OH 
Accepting New Patients
Advanced in Corneal Dystrophy and Perceptive Deafness
Spectrum Eye Care, Inc.
15840 Medical Dr S, Suite A, 
Findlay, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pankaj Gupta is an Ophthalmologist in Findlay, Ohio. Dr. Gupta is rated as an Advanced provider by MediFind in the treatment of Corneal Dystrophy and Perceptive Deafness. His top areas of expertise are Meibomianitis, Dry Eye Syndrome, Cataract, Scleritis, and Cataract Removal. Dr. Gupta is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Ophthalmology
Licenses
Ophthalmology in MA
Hospital Affiliations
Mercy Health-St Rita's Medical Center
Blanchard Valley Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Ohio Health Group
  • PPO
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

SPECTRUM EYE CARE, INC.
15840 Medical Dr S, Suite A, Findlay, OH 45840

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
Enrollment Status: Terminated
Publish Date: May 20, 2024
Intervention Type: Drug, Other
Study Drug: Tenofovir Alafenamide
Study Phase: Phase 3
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2
View 12 Less Clinical Trials

8 Total Publications

Impact of physical and chemical parameters on square wave anodic stripping voltammetry for trace Pb2+ detection in water.
Impact of physical and chemical parameters on square wave anodic stripping voltammetry for trace Pb2+ detection in water.
Journal: The Analyst
Published: July 07, 2022
Similar Doctors
Distinguished in Corneal Dystrophy and Perceptive Deafness
Dr. Hooman Harooni
Ophthalmology
Distinguished in Corneal Dystrophy and Perceptive Deafness
Dr. Hooman Harooni
Ophthalmology

Promedica Central Physicians

1180 N Monroe St, 
Monroe, MI 
 (61.1 miles away)
734-243-5300
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Hooman Harooni is an Ophthalmologist in Monroe, Michigan. Dr. Harooni is rated as a Distinguished provider by MediFind in the treatment of Corneal Dystrophy and Perceptive Deafness. His top areas of expertise are Corneal Dystrophy and Perceptive Deafness, Macular Corneal Dystrophy Type 1, Fuchs Dystrophy, and Keratoconus. Dr. Harooni is currently accepting new patients.

Advanced in Corneal Dystrophy and Perceptive Deafness
Dr. Carrie A. Lembach
Ophthalmology
Advanced in Corneal Dystrophy and Perceptive Deafness
Dr. Carrie A. Lembach
Ophthalmology

Eye Physicians, LLC

855 W Market St, 
Lima, OH 
 (36.1 miles away)
614-221-7464
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carrie Lembach is an Ophthalmologist in Lima, Ohio. Dr. Lembach is rated as an Advanced provider by MediFind in the treatment of Corneal Dystrophy and Perceptive Deafness. Her top areas of expertise are Interstitial Keratitis, Fuchs Dystrophy, Macular Corneal Dystrophy Type 1, and Corneal Dystrophy and Perceptive Deafness. Dr. Lembach is currently accepting new patients.

Advanced in Corneal Dystrophy and Perceptive Deafness
Dr. Thomas J. Dingle
Ophthalmology
Advanced in Corneal Dystrophy and Perceptive Deafness
Dr. Thomas J. Dingle
Ophthalmology

Eye Physicians, LLC

855 W Market St, 
Lima, OH 
 (36.1 miles away)
614-221-7464
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Thomas Dingle is an Ophthalmologist in Lima, Ohio. Dr. Dingle is rated as an Advanced provider by MediFind in the treatment of Corneal Dystrophy and Perceptive Deafness. His top areas of expertise are Cataract, Corneal Dystrophy and Perceptive Deafness, Macular Corneal Dystrophy Type 1, and Fuchs Dystrophy. Dr. Dingle is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gupta's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile